EW STOCK FORECAST: After giving 40% returns to investors over 1 year, will the mometum continue in 2022?

EW STOCK FORECAST: After giving 40% returns to investors over 1 year, will the mometum continue in 2022?

EW Stock Forecast: For the Next 24 hours, the stock price of EW is predicted to trade between $ 115.94 and $ 122.70. The Overall recommendation for next 24 hours is buy.

2 of 3 momentum indicators are positive

EW is trading 2.13% higher at $ 122.12 in the last trading session.

    Metric  Value
Market Cap7.6 B
        Share Volume  6M
    Average Share Volume2 M
     Forward PE (1year)  52.91
EW stock forecast

EW Stock Forecast: Momentum Summary

MetricIndicator
PriceHigher
Technical indicatorsBuy
SentimentNA

EW Stock Forecast: Performance Chart

1 Day5 Days1 month1 year
EW Stock2.13%0.24%4.35%42.60%

EW Stock Forecast: Technical Analysis

AnalystS3R1Recommendation
Investing.com114.52121.76Buy
Barchart.com117.37123.65Buy

EW Stock Forecast: Latest Videos

Edwards Lifesciences CEO on outlook for 2022: ‘We are just getting started’

YouTube video

EW Stock Forecast: Sentiment Analysis

DayPositiveNegativeIndicator
Day 70%6%Negative
Day 1NANANA

Also Read: Moderna Stock Forecast

EW Stock Forecast: Latest News and Tweets

vig.io on Twitter: “$EW is on the move: +1.74%⁣⁣Edwards Lifesciences shares are trading higher after JP Morgan upgraded the stock from Neutral to Overweight and announced a $140 price target. / Twitter”

EW is on the move: +1.74%⁣⁣Edwards Lifesciences shares are trading higher after JP Morgan upgraded the stock from Neutral to Overweight and announced a $140 price target.

Ew Healthcare Partners Fund 2, Buys 5,050 Shares of TELA Bio, Inc. (NASDAQ:TELA) Stock

EW Stock Forecast: Company Background

Edward lifesciences is an American based medical technology company. It was founded in the year 1958 in Irvine, California. The company works on Artificial heart valves and hemodynamic monitoring and produces new technologies to treat late cardiovascular diseases. It was founded by an engineer Miles Lowell Edwards.

EW Stock Forecast: Q3 Results

  • Sales increased 15% to 1.3 billion as of on 30th September
  • Increased 15% in TAVR sales
  • Increased in US TAVR sales by 12% and OUS approximately 20%
  • Full year 2021 sales guidance range changed
  • EW reported that TAVR sales are $858 million in this third quarter of the financial year
  • With 7% increase compared to third quarter of the last year surgical structural heart sales were $217 million
  • The adjusted gross profit margin was 76.3% compared to 75.5% in the third quarter of last financial year.
  • Research and development expenses were $238 million by an increase of 22%
  • Free cash flow was $471 million and cash flow from operating activities is $532 million

-Rakesh Atla

Subhash

Subhash

Subhash, Founder of Crowdwisdom360 is an MBA and a Trained Financial Advisor with an extensive background in Forecasting in Financial Services and Politics. He has appeared many times on National TV and has written for a variety of magazines on Wealth Management and Election Strategy.